Retatrutide: The Triple Agonist GLP-1 Complete Guide (2026)
Retatrutide is Eli Lilly's triple hormone receptor agonist — the first drug to simultaneously activate GLP-1, GIP, and glucagon receptors. Phase 3 data shows 28.7% mean body weight reduction. Here's everything you need to know.